SCHEMBL25209802

SCHEMBL25209802

Cc1ccc(S(=O)(=O)n2cc(-c3ccc4ncccc4c3)c3c(Cl)ncnc32)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.45
ALDH1A1 P00352 3/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
SRC P12931 4/20 0.40
PIK3CA P42336 3/20 0.40
PIK3CD O00329 2/20 0.40
ABL1 P00519 2/20 0.40
EGFR P00533 2/20 0.40
HCK P08631 2/20 0.40
KDR P35968 2/20 0.40
PIK3CB P42338 2/20 0.40
MTOR P42345 2/20 0.40
PIK3CG P48736 2/20 0.40
EPHB4 P54760 2/20 0.40
PRKDC P78527 2/20 0.40
PTPN11 Q06124 1/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30349392 1.00 L3MBTL1 (0.45) L3MBTL1ALDH1A1LMNASMN1; SMN2SRC
SCHEMBL30542285 0.89 L3MBTL1 (0.45) L3MBTL1ALDH1A1LMNASMN1; SMN2PIK3CA
SCHEMBL30399768 0.88 L3MBTL1 (0.48) L3MBTL1ALDH1A1LMNASMN1; SMN2PIK3CA
SCHEMBL26176365 0.88 L3MBTL1 (0.48) L3MBTL1ALDH1A1LMNASMN1; SMN2PIK3CA
SCHEMBL30349319 0.83 EGFR (0.42) L3MBTL1ALDH1A1LMNASMN1; SMN2SRC
SCHEMBL25211151 0.83 EGFR (0.42) L3MBTL1ALDH1A1LMNASMN1; SMN2SRC
SCHEMBL20292779 0.82 L3MBTL1 (0.53) L3MBTL1ALDH1A1LMNASMN1; SMN2PTPN11
SCHEMBL20210703 0.82 L3MBTL1 (0.53) L3MBTL1ALDH1A1LMNASMN1; SMN2SRC
SCHEMBL7060611 0.82 SRC (0.49) L3MBTL1ALDH1A1LMNASMN1; SMN2SRC
SCHEMBL30400147 0.79 L3MBTL1 (0.44) L3MBTL1ALDH1A1LMNASMN1; SMN2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 L3MBTL1 2548/4885ALDH1A1 3447/4885LMNA 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.